Health

TCR-2 THERAPEUTICS TO PRESENT AT THE JEFFERIES CELL AND GENETIC MEDICINE SUMMIT

Cambridge – TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of new T-cell therapies for patients with solid tumors, announced today that the department will participate in a side talk at the Jefferies Cell & Genetic Medicine Summit on Monday. Thursday, September 29 in 2:00 p.m. Eastern time

A live broadcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days after your presentation.

Read:Teen who cares for gran full-time gets 3 A*s at A Level and will study medicine

Around TCR2 . Therapies

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company that is developing a pipeline of novel T-cell therapies for patients with solid tumors. The company is focused on discovering and developing candidate products against new and complex targets using its proprietary T-cell receptor (TCR) Fusion Construct T cells (TRuC-T cells). The TRuC platform is designed to specifically recognize and kill tumor cells by fully harnessing the signals from the TCR, independent of human leukocyte antigen (HLA).

Contact:

Karl Mauch

Read:Tutum Medical’s BEAMS wins Building Better Healthcare Award

Tel: (617) 949 5667

Email: [email protected]

(c) 2022 e-newsletter, source ENP Newswire

Previous post
It remains a seller’s market, says Propertymark
Next post
Ukraine 0 – 0 Scotland